The role of lipid peroxidation in neurological disorders

Journal of Clinical Biochemistry and Nutrition

Volumn 54, Issue 3, 2014, Pages 151-160

  Shichiri, Mototada ^a  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

Alzheimer's disease; Down syndrome; Lipid peroxidation; Neurological disorder; Parkinson's disease; Stroke

Indexed keywords

ALPHA TOCOPHEROL; CHOLESTEROL; DOCOSAHEXAENOIC ACID; FREE RADICAL; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; CEREBROVASCULAR ACCIDENT; CHEMICAL STRUCTURE; DOWN SYNDROME; HUMAN; LIPID PEROXIDATION; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW;

EID: 84900439903     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.14-10     Document Type: Review

References (90)

1. Sies H. Oxidative stress: oxidants and antioxidants. Exp physiol 1997; 82: 291-295. (Pubitemid 27182306)
2. Miyamoto S, Kawano H, Hokamaki J, et al. Increased plasma levels of thioredoxin in patients with glucose intolerance. Intern Med 2005; 44: 1127-1132.
3. Cracowski JL. Isoprostanes: an emerging role in vascular physiology and disease? Chem Phys Lipids 2004; 128: 75-83.
4. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006; 97: 1634-1658. (Pubitemid 43873658)
5. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956; 11: 298-300.
6. Reed TT. Lipid peroxidation and neurodegenerative disease. Free Radic Biol Med 2011; 51: 1302-1319.
7. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004; 5: 863-873. (Pubitemid 39482155)
8. Malinska D, Kudin AP, Debska-Vielhaber G, Vielhaber S, Kunz WS. Chapter 23 Quantification of superoxide production by mouse brain and skeletal muscle mitochondria. Methods Enzymol 2009; 456: 419-437.
9. Chen CT, Green JT, Orr SK, Bazinet RP. Regulation of brain polyunsaturated fatty acid uptake and turnover. Prostaglandins Leukot Essent Fatty Acids 2008; 79: 85-91.
10. Niki E, Yoshida Y, Saito Y, Noguchi N. Lipid peroxidation: mechanisms, inhibition, and biological effects. Biochem Biophys Res Commun 2005; 338: 668-676. (Pubitemid 41540614)
11. Pryor WA, Houk KN, Foote CS, et al. Free radical biology and medicine: it's a gas, man! Am J Physiol Regul Integr Comp Physiol 2006; 291: R491-R511. (Pubitemid 44352329)
12. Panasenko OM, Vakhrusheva TV, Vlasova, II, Chekanov AV, Baranov YV, Sergienko VI. Role of myeloperoxidase-mediated modification of human blood lipoproteins in atherosclerosis development. Bull Exp Biol Med 2007; 144: 428-431.
13. Schneider C, Pratt DA, Porter NA, Brash AR. Control of oxygenation in lipoxygenase and cyclooxygenase catalysis. Chem Biol 2007; 14: 473-488. (Pubitemid 46765155)
14. Ceaser EK, Moellering DR, Shiva S, et al. Mechanisms of signal transduction mediated by oxidized lipids: the role of the electrophile- responsive proteome. Biochem Soc Trans 2004; 32: 151-155. (Pubitemid 38283038)
15. Zmijewski JW, Landar A, Watanabe N, Dickinson DA, Noguchi N, Darley-Usmar VM. Cell signalling by oxidized lipids and the role of reactive oxygen species in the endothelium. Biochem Soc Trans 2005; 33: 1385-1389. (Pubitemid 41779694)
16. Umeno A, Shichiri M, Ishida N, et al. Singlet oxygen induced products of linoleates, 10- and 12-(Z,E)-hydroxyoctadecadienoic acids (HODE), can be potential biomarkers for early detection of type 2 diabetes. PLoS one 2013; 8: e63542.
17. Yoshida Y, Shichiri M. Quantitative analysis of lipid peroxidation products using mass spectrometry. In: Ivanov AR, Lazarev AV, eds. Sample Preparation in Biological Mass Spectrometry, Springer, 2011; 877-884.
18. Yin H, Xu L, Porter NA. Free radical lipid peroxidation: mechanisms and analysis. Chem Rev 2011; 111: 5944-5972.
19. Yamamoto S. Mammalian lipoxygenases: molecular structures and functions. Biochim Biophys Acta 1992; 1128: 117-131.
20. Roman RJ, Renic M, Dunn KM, Takeuchi K, Hacein-Bey L. Evidence that 20-HETE contributes to the development of acute and delayed cerebral vasospasm. Neurol Res 2006; 28: 738-749. (Pubitemid 44656100)
21. Ward NC, Croft KD, Blacker D, et al. Cytochrome P450 metabolites of arachidonic acid are elevated in stroke patients compared with healthy controls. Clin Sci 2011; 121: 501-507.
22. Renic M, Klaus JA, Omura T, et al. Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab 2009; 29: 629-639.
23. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990; 87: 9383-9387. (Pubitemid 120030630)
24. Halliwell B, Lee CY. Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Antioxid Redox Signal 2010; 13: 145-156.
25. Roberts LJ, 2nd, Fessel JP. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Chem Phys Lipids 2004; 128: 173-186. (Pubitemid 38167386)
26. Montine TJ, Beal MF, Cudkowicz ME, et al. Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999; 52: 562-565. (Pubitemid 29075604)
27. Montine TJ, Beal MF, Robertson D, et al. Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease. Neurology 1999; 52: 1104-1105. (Pubitemid 29161638)
28. Fessel JP, Hulette C, Powell S, Roberts LJ 2nd, Zhang J. Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J Neurochem 2003; 85: 645-650. (Pubitemid 36531927)
29. Milne GL, Gao B, Terry ES, Zackert WE, Sanchez SC. Measurement of F2-isoprostanes and isofurans using gas chromatography-mass spectrometry. Free Radic Biol Med 2013; 59: 36-44.
30. Roberts LJ, 2nd, Montine TJ, Markesbery WR, et al. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998; 273: 13605-13612. (Pubitemid 28268404)
31. 4- neuroprostanes levels in cerebrospinal fluid with outcome of aneurysmal subarachnoid hemorrhage in humans. Free Radic Biol Med 2009; 47: 814-824.
32. 4-neuroprostanes mediate neurological severity in Rett syndrome. Clin Chim Acta 2011; 412: 1399-1406.
33. Song WL, Lawson JA, Reilly D, et al. Neurofurans, novel indices of oxidant stress derived from docosahexaenoic acid. J Biol Chem 2008; 283: 6-16.
34. Solberg R, Longini M, Proietti F, Vezzosi P, Saugstad OD, Buonocore G. Resuscitation with supplementary oxygen induces oxidative injury in the cerebral cortex. Free Radic Biol Med 2012; 53: 1061-1067.
35. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 2003; 42: 318-343. (Pubitemid 36411689)
36. Ghilarducci DP, Tjeerdema RS. Fate and effects of acrolein. Rev Environ Contam Toxicol 1995; 144: 95-146.
37. Toyokuni S, Miyake N, Hiai H, et al. The monoclonal antibody specific for the 4-hydroxy-2-nonenal histidine adduct. FEBS Lett 1995; 359: 189-191.
38. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997; 68: 2092-2097. (Pubitemid 27176147)
39. Diczfalusy U. Analysis of cholesterol oxidation products in biological samples. J AOAC Int 2004; 87: 467-473.
40. Lund EG, Guileyardo JM, Russell DW. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci U S A 1999; 96: 7238-7243. (Pubitemid 29299645)
41. Leoni V, Caccia C. 24S-hydroxycholesterol in plasma: a marker of cholesterol turnover in neurodegenerative diseases. Biochimie 2013; 95: 595-612.
42. Björkhem I. Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J Intern Med 2006; 260: 493-508. (Pubitemid 44772369)
43. Lutjohann D, Papassotiropoulos A, Bjorkhem I, et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 2000; 41: 195-198. (Pubitemid 30117859)
44. Niki E. Tocopherylquinone and tocopherylhydroquinone. Redox Rep 2007; 12: 204-210. (Pubitemid 350065107)
45. Stoyanovsky DA, Osipov AN, Quinn PJ, Kagan VE. Ubiquinone-dependent recycling of vitamin E radicals by superoxide. Arch Biochem Biophys 1995; 323: 343-351.
46. Ravaglia G, Forti P, Lucicesare A, et al. Plasma tocopherols and risk of cognitive impairment in an elderly Italian cohort. Am J Clin Nutr 2008; 87: 1306-1313. (Pubitemid 351679774)
47. Kanazawa H, Miyata C, Nagata Y, Urano S, Matsushima Y. Determination of alpha-tocopherol and alpha-tocopherylquinone in rat tissues and plasma by high-performance liquid chromatography with electrochemical detection. Chem Pharm Bull (Tokyo) 2000; 48: 1462-1466.
48. Murphy ME, Kolvenbach R, Aleksis M, Hansen R, Sies H. Antioxidant depletion in aortic crossclamping ischemia: increase of the plasma alpha-tocopheryl quinone/alpha-tocopherol ratio. Free Radic Biol Med 1992; 13: 95-100.
49. Shichiri M, Yoshida Y, Ishida N, et al. α-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome. Free Radic Biol Med 2011; 50: 1801-1811.
50. Shichiri M, Harada N, Ishida N, et al. Oxidative stress is involved in fatigue induced by overnight deskwork as assessed by increase in plasma tocopheryl-hydroqinone and hydroxycholesterol. Biol Psychol 2013; 94: 527-533.
51. Huang X, Atwood CS, Hartshorn MA, et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999; 38: 7609-7616. (Pubitemid 29289332)
52. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 2001; 7: 548-554. (Pubitemid 33127140)
53. Praticò D, Uryu K, Leight S, Trojanoswki JQ, Lee VM. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001; 21: 4183-4187. (Pubitemid 32538543)
54. Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 2005; 58: 730-735. (Pubitemid 41552548)
55. Montine TJ, Montine KS, McMahan W, Markesbery WR, Quinn JF, Morrow JD. F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal 2005; 7: 269-275. (Pubitemid 40187943)
56. Reed TT, Pierce WM, Markesbery WR, Butterfield DA. Proteomic identification of HNE-bound proteins in early Alzheimer disease: insights into the role of lipid peroxidation in the progression of AD. Brain Res 2009; 1274: 66-76.
57. Volkel W, Sicilia T, Pähler A, et al. Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer's disease. Neurochem Int 2006; 48: 679-686.
58. Liu Q, Smith MA, Avilá J, et al. Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic Biol Med 2005; 38: 746-754. (Pubitemid 40249745)
59. Yoshida Y, Yoshikawa A, Kinumi T, et al. Hydroxyoctadecadienoic acid and oxidatively modified peroxiredoxins in the blood of Alzheimer's disease patients and their potential as biomarkers. Neurobiol Aging 2009; 30: 174-185.
60. Bretillon L, Sidén A, Wahlund LO, et al. Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci Lett 2000; 293: 87-90.
61. Papassotiropoulos A, Lütjohann D, Bagli M, et al. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport 2000; 11: 1959-1962.
62. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379-2388. (Pubitemid 40958434)
63. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336: 1216-1222. (Pubitemid 27183651)
64. Lloret A, Badía MC, Mora NJ, Pallardó FV, Alonso MD, Viña J. Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis 2009; 17: 143-149.
65. Groner Y, Elroy-Stein O, Avraham KB, et al. Cell damage by excess CuZnSOD and Down's syndrome. Biomed Pharmacother 1994; 48: 231-240. (Pubitemid 24210135)
66. Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995; 378: 776-779. (Pubitemid 26004408)
67. Perrone S, Longini M, Bellieni CV, et al. Early oxidative stress in amniotic fluid of pregnancies with Down syndrome. Clin Biochem 2007; 40: 177-180. (Pubitemid 46108711)
68. Odetti P, Angelini G, Dapino D, et al. Early glycoxidation damage in brains from Down's syndrome. Biochem Biophys Res Commun 1998; 243: 849-851. (Pubitemid 28414171)
69. Moldrich RX, Dauphinot L, Laffaire J, Rossier J, Potier MC. Down syndrome gene dosage imbalance on cerebellum development. Prog Neurobiol 2007; 82: 87-94. (Pubitemid 46829600)
70. Ellis JM, Tan HK, Gilbert RE, et al. Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial. BMJ 2008; 336: 594-597. (Pubitemid 351439516)
71. Jellinger KA. Recent developments in the pathology of Parkinson's disease. J Neural Transm Suppl 2002; 347-376. (Pubitemid 37046679)
72. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-840.
73. Turnbull S, Tabner BJ, El-Agnaf OM, Moore S, Davies Y, Allsop D. alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic Biol Med 2001; 30: 1163-1170. (Pubitemid 32441842)
74. Xu S, Zhou M, Yu S, et al. Oxidative stress induces nuclear translocation of C-terminus of alpha-synuclein in dopaminergic cells. Biochem Biophys Res Commun 2006; 342: 330-335. (Pubitemid 43247395)
75. Castellani RJ, Perry G, Siedlak SL, et al. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett 2002; 319: 25-28. (Pubitemid 34117635)
76. Qin Z, Hu D, Han S, Reaney SH, Di Monte DA, Fink AL. Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J Biol Chem 2007; 282: 5862-5870. (Pubitemid 47093740)
77. Seet RC, Lee CY, Lim EC, et al. Oxidative damage in Parkinson disease: measurement using accurate biomarkers. Free Radic Biol Med 2010; 48: 560-566.
78. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994; 36: 348-355. (Pubitemid 24280055)
79. Ambani LM, Van Woert MH, Murphy S. Brain peroxidase and catalase in Parkinson disease. Arch Neurol 1975; 32: 114-118.
80. Saito Y, Hamakubo T, Yoshida Y, et al. Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients. Neurosci Lett 2009; 465: 1-5.
81. Kinumi T, Kimata J, Taira T, Ariga H, Niki E. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004; 317: 722-728. (Pubitemid 38481432)
82. Akazawa YO, Saito Y, Hamakubo T, et al. Elevation of oxidized DJ-1 in the brain and erythrocytes of Parkinson disease model animals. Neurosci Lett 2010; 483: 201-205.
83. Zhang SM, Hernán MA, Chen H, Spiegelman D, Willett WC, Ascherio A. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 2002; 59: 1161-1169. (Pubitemid 35192385)
84. Etminan M, Gill SS, Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurol 2005; 4: 362-365. (Pubitemid 40720032)
85. Weber CA, Ernst ME. Antioxidants, supplements, and Parkinson's disease. Ann Pharmacother 2006; 40: 935-938. (Pubitemid 43765012)
86. Feigin VL. Stroke epidemiology in the developing world. Lancet 2005; 365: 2160-2161. (Pubitemid 40853896)
87. Crack PJ, Taylor JM. Reactive oxygen species and the modulation of stroke. Free Radic Biol Med 2005; 38: 1433-1444. (Pubitemid 40693828)
88. Gursoy-Ozdemir Y, Can A, Dalkara T. Reperfusion-induced oxidative/nitrative injury to neurovascular unit after focal cerebral ischemia. Stroke 2004; 35: 1449-1453. (Pubitemid 38697474)
89. Hirashima Y, Doshi M, Hayashi N, et al. Plasma platelet-activating factor-acetyl hydrolase activity and the levels of free forms of biomarker of lipid peroxidation in cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 2012; 70: 602-609.
90. Green AR. Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly. Br J Pharmacol 2008; 153: S325-S338. (Pubitemid 351340997)